SAN FRANCISCO, Dec. 04, 2023 Olema Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for.
Presentations detailing initial Phase 1b clinical data for palazestrant in combination with ribociclib, a Poster Spotlight Session on Phase 2 clinical data for palazestrant in combination with.
Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
SAN FRANCISCO, Nov. 01, 2023 Olema Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for.